Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
Become a Member | Sign in
Home>News>This Article

Nodality Announces Publication of Promising Data in Melanoma in JTM

Published: Friday, May 30, 2014
Last Updated: Thursday, May 29, 2014
Bookmark and Share
Nodality's SCNP platform holds strong potential in aiding the development of new cancer and immuno-oncology treatments.

Nodality, Inc. has announced promising data utilizing the company's proprietary Single Cell Network Profiling (SCNP) technology in metastatic melanoma. Nodality's SCNP technology reveals functional biology underlying the most important and intractable diseases, providing critical insights to help guide the discovery and development of next-generation therapeutic agents.

According to data published in the current issue of the Journal of Translational Medicine (JTM), Nodality's researchers have identified key biomarkers in the blood that can help predict responses to new therapies for melanoma, including cancer immunotherapeutics.

“While there has been exciting recent progress in the treatment of melanoma, new therapies have been found to benefit only a subset of patients and are often associated with significant adverse effects,” commented Laura Brege, Nodality's President and Chief Executive Officer.

Brege continued, “With our highly sensitive and reproducible SCNP platform, we are able to attain a deep, functional understanding of how the immune system behaves in the presence of tumor cells and how cancer cells vary in their response to approved and promising development-stage therapies. In light of SCNP's broad range of capabilities and potential applications, we believe our technology can play an essential role in advancing pipelines of targets and therapeutics to deliver the next generation of drugs for cancer and other major illnesses.”

For access to the JTM article, titled “Systems biology analysis of immune signaling in peripheral blood mononuclear cells (PBMC) of melanoma patients receiving ipilimumab; basis for response biomarker identification,” please visit

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
NIH Supports New Studies to Find Alzheimer’s Biomarkers in Down Syndrome
Initiative will track dementia onset, progress in Down syndrome volunteers.
New Gene Map Reveals Cancer’s Achilles’ Heel
Team of researchers switches off almost 18,000 genes
Genetic Basis of Fatal Flu Side Effect Discovered
A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a recent study.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Mathematical Model Forecasts the Path of Breast Cancer
Chances of survival depend on which organs breast cancer tumors colonize first.
Ancient Viral Molecules Essential for Human Development
Genetic material from ancient viral infections is critical to human development, according to researchers at the Stanford University School of Medicine.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Personalized Drug Screening for Multiple Myeloma Patients
A personalized method for testing the effectiveness of drugs that treat multiple myeloma may predict quickly and more accurately the best treatments for individual patients with the bone marrow cancer.
Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
New Way to Force Stem Cells to Become Bone Cells
Potential therapies based on this discovery could help people heal bone injuries or set hardware, such as replacement knees and hips.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos